Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q4 2025: Roche 17.1305, AstraZeneca 15.384.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Roche vs AstraZeneca Net Worth and Market Cap
Roche (RHHBY) and AstraZeneca (AZN) are peers in GLP-1. Roche reported revenue of $34.3B as of Q4 2025, compared with $15.4B for AstraZeneca. Roche leads on revenue.
Roche's gross margin is 71.7% versus 83.6% for AstraZeneca. Roche's net margin is 17.9% versus 16.3% for AstraZeneca.
Key differences
- Revenue growth on the same quarter a year earlier: AstraZeneca +6.4% (Q2 2026), Roche -4.2% (Q4 2025).
- Roche's KPIs on Sterling include Carmot Asset Pipeline: CT-388, CT-996, CT-868 Trial Readout Timeline and CT-868 (Acmopatide) Discontinuation.
- AstraZeneca's KPIs on Sterling include Alliance Revenue by Partnered Medicine (Quarterly) and AZD5004 + AZD6234 Trial Timeline: Oral GLP-1 + Oral Amylin.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Roche, AstraZeneca.| Metric | Roche | AstraZeneca |
|---|---|---|
| Market Cap | - | - |
| Revenue | $34.26B | $15.38B |
| Cost of Revenue | $9.68B | $2.52B |
| Gross Profit | $24.58B | $12.86B |
| Operating Income | $7.96B | $3.16B |
| Net Income | $6.13B | $2.51B |
| R&D Expense | $7.48B | $4.05B |
| Earnings Per Share | $0.95 | $1.59 |
| Gross Margin | 71.7% | 83.6% |
| Operating Margin | 23.2% | 20.6% |
| Net Profit Margin | 17.9% | 16.3% |
| Free Cash Flow | $10.67B | $2.13B |
| Cumulative Free Cash Flow | $299.34B | $121.22B |
| Operating Cash Flow | $13.12B | $2.89B |
| Cash & Equivalents | $6.32B | $4.89B |